Shilpa Medicare Limited (IN:SHILPAMED)
:SHILPAMED
Want to see IN:SHILPAMED full AI Analyst Report?
SHILPAMED Stock Chart & Stats
₹319.90
-₹8.10(-0.96%)
At close: 4:00 PM EST
₹319.90
-₹8.10(-0.96%)
Day’s Range― - ―
52-Week Range₹260.00 - ₹531.90
Previous CloseN/A
Volume218.26K
Average Volume (3M)38.83K
Market Cap
₹100.85B
Enterprise Value₹103.73B
Total Cash (Recent Filing)₹535.50M
Total Debt (Recent Filing)₹5.93B
Price to Earnings (P/E)42.3
Beta0.86
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.16%
Share Statistics
EPS (TTM)7.01
Shares Outstanding195,581,820
10 Day Avg. Volume85,780
30 Day Avg. Volume38,829
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.63
Price to Sales (P/S)4.43
P/FCF Ratio-90.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.95
Revenue Forecast (FY)₹16.94B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth since FY2023, with acceleration into FY2026, implies improving product demand and market penetration. Over a 2–6 month horizon this supports scale economies, steadier contract volumes and R&D funding, reducing execution risk and enabling longer-term margin expansion.
Improved ProfitabilityMaterial margin improvement and strong FY2026 operating metrics indicate better cost absorption and pricing power in core APIs/ formulations. If sustained, higher operating margins strengthen internal reinvestment capacity and free up resources for strategic R&D or contract-manufacturing expansion over the medium term.
Conservative LeverageLower leverage and a growing equity base provide financial flexibility to fund capex and working capital needs without excessive refinancing risk. A conservative balance sheet increases resilience to industry cycles and supports longer-term strategic investments or M&A if cash conversion improves.
Bears Say
Persistent Negative FCFConsistent negative free cash flow, even in a profitable year, indicates earnings are not translating into surplus cash after investments. Over months this constrains the firm's ability to self-fund growth, increases reliance on external financing and limits sustainable shareholder distributions.
Weak Cash ConversionLow operating cash flow coverage versus reported earnings signals poor cash conversion and potentially elevated working capital or capex needs. Structurally weak conversion raises liquidity risk during shocks, elevates cost of capital, and may force strategic trade-offs in investment vs. debt repayment.
Earnings VolatilityLarge swings in margins and prior periods of negative ROE show earnings sensitivity to product mix or cost pressures. Persistent volatility undermines predictability of returns and complicates planning for capacity and R&D, raising execution risk for sustained profitability over the medium term.
Shilpa Medicare Limited News
SHILPAMED FAQ
What was Shilpa Medicare Limited’s price range in the past 12 months?
Shilpa Medicare Limited lowest stock price was ₹260.00 and its highest was ₹531.90 in the past 12 months.
What is Shilpa Medicare Limited’s market cap?
Shilpa Medicare Limited’s market cap is ₹100.85B.
When is Shilpa Medicare Limited’s upcoming earnings report date?
Shilpa Medicare Limited’s upcoming earnings report date is Aug 06, 2026 which is in 62 days.
How were Shilpa Medicare Limited’s earnings last quarter?
Shilpa Medicare Limited released its earnings results on May 22, 2026. The company reported ₹3.3 earnings per share for the quarter, the consensus estimate of ₹3.3 by ₹0.
Is Shilpa Medicare Limited overvalued?
According to Wall Street analysts Shilpa Medicare Limited’s price is currently Overvalued.
Does Shilpa Medicare Limited pay dividends?
Shilpa Medicare Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.16%. See more information on Shilpa Medicare Limited dividends here
What is Shilpa Medicare Limited’s EPS estimate?
Shilpa Medicare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shilpa Medicare Limited have?
Shilpa Medicare Limited has 195,581,820 shares outstanding.
What happened to Shilpa Medicare Limited’s price movement after its last earnings report?
Shilpa Medicare Limited reported an EPS of ₹3.3 in its last earnings report, expectations of ₹3.3. Following the earnings report the stock price went up 3.778%.
Which hedge fund is a major shareholder of Shilpa Medicare Limited?
Currently, no hedge funds are holding shares in IN:SHILPAMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shilpa Medicare Limited
Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (API's), intermediates, and formulations in India, the United States, Europe, and internationally. It offers oncology and non-oncology API's.; and new drug delivery systems, peptides/biotech products, specialty chemicals, etc. The company also provides contract manufacturing of various dosage forms, such as tablets, capsules, liquid injections, lyophilized injectables, and sterile dry powder injectables. It is also involved in the wind power generation activities. Shilpa Medicare Limited was incorporated in 1987 and is headquartered in Raichur, India.
Technical Analysis
Akums Drugs and Pharmaceuticals Limited
―
Alembic Pharmaceuticals Limited
―
Caplin Point Laboratories Limited
―
Jubilant Pharmova Limited
―
Strides Pharma Science Ltd
―